Company Overview and News

KLCI falls 0.57% as China calls off trade talks with US

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI fell 0.57% at the midday breakin line with the tumble at most regional markets after China called off the trade talks with US officials.
APEXF 7090 UPBMF 5031 5202 2089 9334 6033 7123 5199 KLKBY 2445 PNADF 5347 3026 3867 0026 TNABY 5819 2836 1902 TNABF HIPEF PNAGF

Limited impact seen from Indonesia moratorium

LOCAL planters with operations in Indonesia are not expected to be severely impacted by the latter’s recent decision to impose a three-year moratorium on new oil palm plantations, according to analysts.
KLKBY 2445 SMEBF 2216 4197 2291

KLCI up 0.39% in tandem with regional uptrend

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.39% at midday break Friday, tracking gains at regional markets, as worries over the US-China trade tensions abated somewhat.
7084 7052 GMALF 5681 BATS 4162 5134 7079 GMALY 5139 KLKBY 2445 3301 4715 7216 0900 0026 2836

KLCI remains firmly above 1,800-level

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI remained firmly above the 1,800-point level at mid-morning and was up 0.37%, tracking the gains at regional markets.
HLFBF 7084 7052 1082 BATS 4162 7374 0089 5139 KLKBY 2445 3301 7216 0900 0026 2836

KL Kepong property unit’s profit contribution expected to grow

2018-09-21 theedgemarkets
Kuala Lumpur Kepong Bhd (Sept 20, RM25) Maintain buy with an unchanged target price of RM27.38: We visited Kuala Lumpur Kepong Bhd’s (KLK) property development project in Bandar Seri Coalfields (BSC) and returned feeling positive on the company’s property division’s long-term prospects. BSC is a 1,001-acre (405ha) freehold township development in Sungai Buloh, Selangor. It is located approximately 45km from the Kuala Lumpur city centre.
KLKBY 2445

Demand for CPO expected to pick up towards 4Q of 2018

2018-09-14 theedgemarkets
Plantation sector Maintain neutral: Malaysia’s crude palm oil (CPO) production increased for a second straight month in August, rising by 7.9% month-on-month (m-o-m) to 1.62 million tonnes. The fresh fruit bunch (FFB) yield also improved across Peninsular Malaysia, Sabah and Sarawak, rising by 8.7%, 3.2% and 12.6% year-on-year (y-o-y) respectively to 1.38 tonnes/ha, 1.28 tonnes/ha and 1.52 tonnes/ha.
KLKBY 2445 5138 2216 4383 2291 4243 5012

KLCI reverses gains, slips below 1,800-level

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI reversed much of its gains at mid-morning today and slipped below the 1,800-level, in line with wobbly regional markets.
7036 7113 5681 TPGVF 9334 6033 7123 5199 TGLVY KLKBY 5238 2445 PNADF 3026 0118 HIPEF PNAGF 3719

Planters surprised by govt decision to freeze oil palm acreage expansion

LOCAL planters have been taken by surprise by the Government’s latest decision to stop increasing the planted area for oil palm.
KLKBY 2445 2593

Two Malaysian firms in Forbes Fab 50 list, one makes magazine’s cover

2018-09-06 malaymail - 1
KUALA LUMPUR, Sept 6 ― Malaysia’s Press Metal Aluminium and Batu Kawan both squeezed into this year’s Forbes 50 list that was increasingly dominated by Chinese corporations.
KLKBY 2445 1899 8869 0700

KLCI remains in the red as select blue chips drag

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): The FBM KLCI remained in negative zone at mid-morning today, dragged by losses at select index-linked blue chips.
UPBMF 8621 6432 BATS 4162 2089 5014 8311 5199 7079 7617 KLKBY 5029 2445 4588 4456 3026 6888 MYPRY AXXTF HIPEF 3719

KLCI extends poor start to September, tracks fall at regional markets

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): The FBM KLCI extended its poor start to September this morning, tracking the fall at most regional markets in early trade Tuesday.
KLKBY 2445 5216 5200 7277

KLCI starts September on muted note

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): The FBM KLCI got off to a muted start in September against the backdrop of mixed regional markets, weighed by key index-linked blue chips.
HLFBF 5071 1082 3794 6033 KLKBY 2445 PNADF 4863 6888 AXXTF MYTEF PNAGF

IJM Corp sees lower FY19 order book replenishment

2018-08-29 theedgemarkets
KUALA LUMPUR: Builder and property developer IJM Corp Bhd expects a lower order book replenishment in the current financial year ending March 31, 2019 (FY19) as it already secured some of the jobs in FY18.
KLKBY 2445 5138 2216

IJM Corp remains committed to plantation unit amid speculation of possible disposal

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): IJM Corp Bhd today described as “mere speculation” news reports that the group has received offers to acquire its 56% stake in IJM Plantations Bhd.
KLKBY 2445 5138 2216

KLCI pares gains as regional markets retreat

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): The FBM KLCI pared some of its gains at the midday break today as regional markets retreated.
0090 7192 7036 5681 BATS 4162 5202 5168 9334 KLKBY 2445 5347 3301 5797 3867 TNABY TNABF HRGHY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 501161202